Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Hormone Receptor-positive Metastatic Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT00626106
What this trial is testing

QUILT-2.015: A Study of AMG 479 With Exemestane or Fulvestrant in Postmenopausal Women With Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast CancerBreast TumorsMetastatic Cancer
NantCell, Inc. 156
Early research (Phase 1)Study completedNCT04483505
What this trial is testing

Rogaratinib, Palbociclib y Fulvestrant in Patients With Breast Cancer.

Who this might be right for
Breast Cancer MetastaticHormone Receptor Positive Malignant Neoplasm of Breast
Fundacion CRIS de Investigación para Vencer el Cáncer 9
Testing effectiveness (Phase 2)Ended earlyNCT06851442
What this trial is testing

Clinical Trial of Evaluating TQB3912 Tablets Combined With Fulvestrant Injection±TQB3616 Capsules for Locally Advanced or Metastatic Hormone Receptor(HR)-Positive and Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer

Who this might be right for
Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 8
Early research (Phase 1)WithdrawnNCT04585724
What this trial is testing

Stereotactic Radiosurgery With Abemaciclib, Ribociclib, or Palbociclib in Treating Patients With Hormone Receptor Positive Breast Cancer With Brain Metastases

Who this might be right for
Anatomic Stage IV Breast Cancer American Joint Committee on Cancer (AJCC) v8Metastatic Breast CarcinomaMetastatic Malignant Neoplasm in the Brain+1 more
Emory University
Large-scale testing (Phase 3)Active Not RecruitingNCT06018337
What this trial is testing

DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)

Who this might be right for
Metastatic Breast Cancer
DualityBio Inc. 541
Testing effectiveness (Phase 2)Looking for participantsNCT04683679
What this trial is testing

Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer

Who this might be right for
Triple Negative Breast CancerTNBC - Triple-Negative Breast CancerBreast Cancer+1 more
Memorial Sloan Kettering Cancer Center 34
Testing effectiveness (Phase 2)Looking for participantsNCT06525766
What this trial is testing

Adaptive Therapy With Capecitabine for Treatment of Metastatic ER Positive, HER2 Negative Breast Cancer

Who this might be right for
Anatomic Stage IV Breast Cancer AJCC v8Estrogen-receptor-positive Breast CancerMetastatic HER2-Negative Breast Carcinoma+1 more
Mayo Clinic 35
Large-scale testing (Phase 3)Looking for participantsNCT05646862
What this trial is testing

A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy

Who this might be right for
Breast Cancer
Hoffmann-La Roche 420
Not applicableEnded earlyNCT02149173
What this trial is testing

F-18 FES PET/CT in Measuring Hormone Expression in Patients With Primary, Recurrent, or Metastatic Breast Cancer Undergoing Endocrine-Targeted Therapy

Who this might be right for
Estrogen Receptor PositiveRecurrent Breast CarcinomaStage IV Breast Cancer AJCC v6 and v7
University of Washington 29
Early research (Phase 1)Active Not RecruitingNCT03332797
What this trial is testing

GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer

Who this might be right for
Breast Cancer
Genentech, Inc. 181
Testing effectiveness (Phase 2)Ended earlyNCT00417885
What this trial is testing

A Clinical Trial Assessing Efficacy and Safety of Sunitinib and Exemestane in Patients With ER [Estrogen Receptor] + and/or PgR [Progesterone Receptor] + Breast Cancer

Who this might be right for
Breast Neoplasms
Pfizer 6
Testing effectiveness (Phase 2)Ended earlyNCT01627067
What this trial is testing

Exemestane-RAD001-Metformin

Who this might be right for
Breast Cancer
M.D. Anderson Cancer Center 23
Early research (Phase 1)Looking for participantsNCT05283330
What this trial is testing

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

Who this might be right for
Cervical CancerBreast CancerColon Cancer+4 more
Orano Med Theranostics, SAS 48
Testing effectiveness (Phase 2)WithdrawnNCT06105008
What this trial is testing

Study of Disitamab Vedotin With Toripalimab Verus Disitamab Vedotin in Hormone Receptor Positive, HER2-low Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Neoplasms
RemeGen Co., Ltd.
Testing effectiveness (Phase 2)Looking for participantsNCT05735080
What this trial is testing

Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer

Who this might be right for
Breast CancerBreast Cancer MetastaticHormone Receptor Positive Tumor+6 more
Incyclix Bio 150
Not applicableStudy completedNCT00735215
What this trial is testing

Faslodex Registry: Fulvestrant in Current Clinical Practice

Who this might be right for
Metastatic Breast Cancer
AstraZeneca 200
Early research (Phase 1)Study completedNCT06745804
What this trial is testing

Study of 68Ga-R10602

Who this might be right for
Locoregionally Recurrent Hormone-receptor Positive Breast CancerMetastatic Hormone Receptor Positive Breast CancerHormone Receptor Positive Breast Adenocarcinoma
Radionetics Oncology 27
Testing effectiveness (Phase 2)Active Not RecruitingNCT04316117
What this trial is testing

Using FDG-PET/CT to Assess Response of Bone-Dominant Metastatic Breast Cancer, FEATURE Study

Who this might be right for
Anatomic Stage IV Breast Cancer AJCC v8Hormone Receptor Positive Breast CarcinomaMetastatic Breast Carcinoma+1 more
ECOG-ACRIN Cancer Research Group 138
Testing effectiveness (Phase 2)Ended earlyNCT06408168
What this trial is testing

Phase II Study of REPotrectinib With or Without Fulvestrant in Patients With Hormone Receptor-positive Human Epidermal Growth Factor 2-negative Metastatic Invasive LObular Carcinoma Who Received a Prior Endocrine Therapy in Combination With Cyclin-dependent Kinase 4 and 6 Inhibitor (REPLOT Trial)

Who this might be right for
Hormone Receptor-positive Human Epidermal Growth Factor 2-negativeMetastatic Invasive LObular Carcinoma
M.D. Anderson Cancer Center 6
Not applicableEnded earlyNCT04967248
What this trial is testing

A NIS of Alpelisib in Combination With Fulvestrant in Postmenopausal Women, and Men, With HR+,HER2- , Locally Advanced or Metastatic Breast Cancer With a PIK3CA Mutation, After Disease Progression Following Endocrine Therapy as Monotherapy, in the Real-world Setting

Who this might be right for
Hormone Receptor Positive HER2 Negative Breast Cancer With a PIK3CA Mutation
Novartis Pharmaceuticals 4
Next Page